Egrifta Misses PDUFA Deadline, On Track For "Action Date"
Executive Summary
After picking up a unanimous advisory committee recommendation, Theratechnologies'Egrifta (tesamorelin) seems in a strong position for approval, but from another perspective, it is four months behind schedule.